OR-AIRSHIP
16.5.2019 15:02:09 CEST | Business Wire | Press release
Customer engagement company Airship today announced May and June dates and locations for its 2019 Customer Engagement Forum , a year-long global event series. These interactive sessions feature leaders from many of the world's leading brands discussing their plans and practices for customer engagement (CX) in a digital world — arming marketers with proven strategies, research and techniques to connect with customers in smarter, faster, and more effective ways.
Dubbed ELEVATE, the educational series will kick-off in Santa Monica on May 21, 2019 and San Francisco on May 30, 2019. In June, the forum series will come to Paris , Chicago , New York , Amsterdam and London . Seats are limited; those interested in attending should reserve their spot using the city-specific links above. Additional cities and dates will be announced later this year.
Featuring a unique collection of speakers in each city, the series will focus on the growing focus on customer experience (CX) as the key driver of many companies’ growth and competitive strategies. Among topics such as CX best practices and innovation, the program will also include a discussion of building a business case for the value of better customer experience (CX).
According to Gartner, “Today, slightly more than two-thirds of marketers responsible for CX say their companies compete on the basis of CX. In two years, this expectation rises even further, with 81% of respondents anticipating their companies will do so.” (Gartner, Customer Experience in Marketing Survey 2017: Greater Expectations, Greater Challenges, Augie Ray, Jane-Anne Mennella, Simon Yates, Refreshed April 9, 2019, Published 5 October 2017).
Customer Engagement Forum attendees will gain a sharper understanding of what’s at stake when it comes to getting customer engagement right — learning about the CX trends experts are watching, as well as the CX tech stack and common team structures. Beyond a notebook full of ideas to leapfrog the competition and crush their KPIs, attendees will gain stats to build a business case for the value of better CX to grow their budgets and their careers.
“Forrester analyzed the correlation between CX quality and revenue growth for companies in five industries ... companies with superior CX grew revenues five times faster on average than their competitors with inferior CX. And this is a global phenomenon” (Forrester Research, Inc., “Improving CX Through Business Discipline Drives Growth,” June 19, 2017; Updated March 26, 2018).
Companies speaking at Customer Engagement Forum events include AccuWeather, AMC Theatres, Expensify, Footlocker, France TV, GSN Games, Tribune Publishing, Turner Sports and Zillow, with more to come.
“Today’s fastest-growing brands separate themselves from the pack by providing unique experiences that deliver surprising convenience and delight to their customers,” said Mike Stone, SVP of Marketing, Airship. “The Airship Customer Engagement Forum provides marketers an incredible opportunity to learn successful CX strategies from leading brands, as well as the programs and tactics to put them into place.”
For more information on Airship’s Customer Engagement Forum 2019, or to register, please visit forum.airship.com .
About Airship
Marketing and digital experience teams at thousands of the world’s most admired companies rely on Airship’s Customer Engagement Platform to create deeper connections with customers by delivering incredibly relevant, orchestrated messages on any channel.
Founded in 2009 as a pioneer in push notifications, Airship now gives brands the user-level data, engagement channels, AI orchestration and services they need to deliver push notifications, emails, SMS, in-app messages, mobile wallet cards and more to exactly the right person in exactly the right moment — building trust, boosting engagement, driving action and growing value.
Learn more about our Customer Engagement Platform , read our blog or follow us on Twitter , LinkedIn and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516005238/en/
Contact:
North America: Dave Struzzi Bateman Group +1 415-697-2560 airship@bateman-group.com
Corey Gault Airship +1 503-206-9164 corey@airship.com
EMEA: Nicolas Vitre Airship +33 1 44 56 88 21 +33 6 88 04 76 86 nicolas.vitre@airship.com
UK: Lucinda Layton Hotwire UK +44 20 7608 2500 Airship@hotwireglobal.com
France: Marion Fajgenbaum / Marine Cressot Hotwire France +33 14 312 55 68 / 69 AirshipFR@hotwireglobal.com
Germany: Julia da Silva Bastos Hotwire Germany +49 89 2620 81 89 airshipde@hotwireglobal.com
Spain: Beatriz Pérez Hotwire Spain +34 917 44 1265 beatriz.perez@hotwireglobal.com
Italy: Sara Tetti Hotwire Italy +39 349 5788052 AirshipIT@hotwireglobal.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom